Senseonics Holdings, Inc.

AMEX•SENS

CEO: Dr. Timothy T. Goodnow Ph.D.

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2015-12-22

Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Contact Information

20451 Seneca Meadows Parkway, Germantown, MD, 20876-7005, United States

301-515-7260

www.senseonics.com

Market Cap

$264.82M

P/E (TTM)

-3.8

3.9

Dividend Yield

52W High

$15.74

52W Low

$5.25

52W Range

10%

Rank53Top 76.1%

2.8

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$14.26M+0.00%

4-Quarter Trend

EPS

-$0.50+0.00%

4-Quarter Trend

FCF

-$23.25M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Grew Substantially Total revenue reached $35.3M, growing $12.8M from $22.5M in 2024, driven by strong US consignment program sales.

Gross Margin Significantly Improved Gross margin expanded sharply to 44.7% in 2025, up from only 2.4% in 2024, aided by product mix and prior year charges.

Net Loss Narrowed Net Loss narrowed by $9.5M to $(69.1M) in 2025, showing operational leverage improvement despite increased SG&A spending.

US Commercial Control Resumed US commercial responsibility fully transitioned back from Ascensia effective January 1, 2026, securing direct market control.

Risk Factors

Profitability Remains Uncertain Incurred substantial net losses since inception; profitability remains uncertain for the foreseeable future requiring additional capital.

Increased Operating Expenses SG&A expenses rose $18.3M to $52.5M, driven by US commercialization launch and associated transition costs.

Going Concern Doubt Exists Substantial doubt exists regarding ability to continue as going concern for next twelve months without securing additional liquidity.

Active Patent Litigation Exposure Facing active patent infringement lawsuit; outcome is inherently unpredictable and could result in material adverse financial impact.

Outlook

European Revenue Entitlement Expect 100% revenue entitlement from European Territories starting January 1, 2026, following definitive agreement finalization.

Next-Gen Product Pipeline Next-generation Gemini and Freedom systems targeted for commercial launch by Q4 2027 and Q4 2028, respectively.

R&D Spending Optimization R&D expenses decreased $9.5M to $31.6M due to completion of pivotal clinical trials for Eversense 365 system.

Prioritize Payor Coverage Prioritizing payor coverage transition for Eversense 365 to secure favorable reimbursement status across US covered lives.

Peer Comparison

Revenue (TTM)

OMI

$2.76B

-41.0%

TOI

$502.73M

+27.8%

TMCI

$212.69M

+1.6%

Gross Margin (Latest Quarter)

ACRS

162.0%

+39.1pp

OMI

93.9%

-2.1pp

SMLR

91.5%

+0.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CAPR	$1.41B	-14.4	-0.1%	4.1%
SRDX	$614.51M	-34.8	-15.6%	19.2%
NPCE	$456.52M	-20.7	-105.7%	67.1%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

31.6%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data